BEST PRICE WORLDWIDE Gerovital Vials - Gerovital H3 (procaine hydrochloride) Original formula made by the Romanian Prof. Aslan.
This is one of Prof. dr. med. Ana Aslan on the preventive and curative treatment of signs of aging:
Ampoule Series: An injectable ampoule on Monday, Wednesday and Friday every week of the month = 12 ampoules / month. One month break or alternate with one month of treatment.
About Gerovital: Discovered by Prof. dr. med. Ana Aslan at the Geriatric Institute of Bucharest, in the early fifties, it is still manufactured today in the factory in Bucharest. This unique nutrient formulation has been described as a "fountain of youth" and is valued at more than 10 million people in more than 70 countries worldwide. Gerovital H3 is the first anti-aging therapy to reduce the activity of free radicals. The complex effects of Gerovital-H3 are at the level of the central and neurovegetative nervous system and at the level of the cells. It has been demonstrated that the product acts on the cell's oxidation-reduction phenomena, stimulation of tissue regeneration and improvement of metabolic processes.It has been proven that in the treatment of: Parkinson,
Pharmaceutical form: Injectable solution - intramuscular
An ampoule contains:
- Procaine hydrochloride (100 mg)
Benzoic acid (6 mg)
- disodium phosphate dodecahydrate (0.5 mg)
- potassium metabisulphite (5 mg)
- Distilled water for injection solutions (up to 5 ml)
Pharmacotherapeutic group: digestive tract and metabolism. Tonic preparations. ATC code: A13 AN01
DEPRESSIVE SYNDROME: mild and moderate depression in early stages, especially when conventional therapy is not well tolerated or contraindications exist;
PARKINSONIC SYNDROME: Where can it be used in monotherapy or in conjunction with other anti-Parkinson drugs, in particular with dopaminergic agents;
OSTEOARTHRITIS: chronic degenerative rheumatism;
Systemic arteriosclerosis: with hypercholesterolemia, ischemic heart disease, arteritis, cerebral atherosclerosis;
Protection against aging phenomena;
Dosage and method of administration:
Gerovital® H3 should be given subcutaneously and after 24 hours the test should be repeated intramuscularly with 1.5 ml of solution. If an allergic reaction occurs, treatment is not recommended.
The recommended dose is 5 ml (1 ampoule) Gerovital H 3 intramuscular injection 3 times a week (1 bottle of Gerovital H 3 solution every two days) for 4 weeks.
Gerovital H 3 tablets daily, after meals, in the morning and in the afternoon for 12 days.
The treatment series wants to be followed annually, continuously or with a one-month break between them. The schedule and frequency of breaks will be decided by the geriatric doctor, depending on the condition of the patient.
1st week: 1 ampoule (5 ml) intramuscular injection / day, 3 times a week (ie Monday, Wednesday and Friday);
2nd week: 1.5 ampoules (7.5 ml) intramuscular injection / day, 3 times a week;
3rd week: 1.5 ampoules (7.5 ml) intramuscular injection / day, 3 times a week;
4th week: 2 ampoules (10 ml) intramuscular injection / day, 3 times a week.
The treatment should be repeated 4-6 times a year.
Total treatment: about 110 ampoules / year
Injectable solution: 1 ampoule (5 ml) intramuscular injection / day for 15 days
Total treatment: approx. 180 ampoules / year
Dragees: 2 tablets / day for 15 days
Total treatment: approx. 360 tablets / year
Injectable solution: 1 ampoule (5 ml) intramuscular injection / day, for 15-21 days and then
1 ampoule (5 ml) intramuscular injection / 3 times a week (every other day) for 4 weeks;
The treatment should be repeated 4-5 times a year.
Total treatment: approx. 160 ampoules / year
Dragees: During the breaks in the injection series, 1-2 tablets / day can be administered for 12-18 days / month.
Total treatment: approx. 180 tablets / year
Depending on the intensity and location of the process, the treatment should be as follows:
Injectable solution: 1 ampoule (5 ml) intramuscular injection / day 3 times a week for 4 weeks.
The treatment should be repeated 5-6 times a year.
Total treatment: approx. 72 ampoules / year
Dragees: Oral treatment may be given between the injection series - 2 dragees / day, 12 days.
Total treatment: approx. 150 tablets / year
Dragees: In some cases, the treatment can only be oral. 3 dragees / day, 21 days in 6-8 series / year
Total treatment: approx. 500 tablets / year
Protection against aging phenomena:
Injectable solution: 1 ampoule (5 ml) intramuscular injection / day, 3 times a week (one ampoule every other day) over a period of 4 weeks
Total treatment: approx. 100 ampoules / year
Dragees: 2 coated tablets / day, after meals, morning and afternoon
Precision for drug administration:
Before starting treatment, a test for individual procaint tolerance should be performed (see "Posology and method of administration").
Treatment must be under medical supervision, mainly in the first series of treatment, to determine the optimal dose.
The product should be used with caution in patients with orthostatic hypotension.
Although it is not recommended to treat cancer patients, it does not excite the potential of the neoplastic cell is not excluded.
Interaction with other medicinal products or other substances:
Gerovital® H3 should not be treated concomitantly with sulfonamides (antagonistic mechanism of action) with the exception of antidiabetic, anticholinesterases: neostygmins, eserine (physostigmine) and pyridostigmine.
Pregnant and lactating women: The animal studies did not show any teratogenic effects. In the absence of teratogenic effects in animals, no malformations in humans are to be expected. However, clinical experience with Gerovital® H3 mainly affects patients over the reproductive period. For the reasons we do not recommend to use the product during pregnancy and lactation.
Potential effects on the ability to drive or use machines: The product does not affect these capabilities.
Side effects that may occur while using the medicine:
Use of Gerovital® H3 may cause allergic reactions in patients with procreative hypersensitivity such as rash or itching.
These effects are an immediate stop of treatment.
Minor effects may occur especially at the beginning of treatment: dizziness, weakness and palpitations. These effects can be avoided after injecting the patient into the bed for 10-15 minutes.
There are no reports of overdose associated with the administration of Gerovital® H3. Accidental injection of high doses may cause severe hypotension, convulsions, coma, respiratory arrest.
The treatment is symptomatic and supports vital signs.
* Save under 25 C.
* Keep away from children.
* Do not use the expiration date printed on the package.
Cardboard box with 5 brown ampoules of 5 ml
Keine Beiträge gefunden.